-
2019 Venture Capital Report
6.4.2019The 2019 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
2019 M&A Report
6.4.2019The 2019 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2019 IPO, Venture Capital and M&A Reports
6.4.2019WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2019 IPO Report
6.4.2019The 2019 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest.
-
WilmerHale Advises Inozyme Pharma in $67 Million Series A2 Financing
4.17.2019Biotechnology company Inozyme Pharma, Inc. announced that it raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments.
-
Four Things Every Smart Startup Should Do as It Scales
4.10.2019This article discusses key areas that startups need to focus on as they mature in order to sidestep “business-busting” distractions and lay the groundwork for healthy company culture.
-
Recent Venture Financings as Company Counsel: 2019
3.14.2019In 2018, we served as counsel in more than 200 venture financings raising close to $4.5 billion, including some of the largest and most prominent deals of the year.
-
WilmerHale Advises Schrödinger in $85 Million Financing Round
1.4.2019Schrödinger, a privately held company revolutionizing drug discovery through advanced molecular simulations, announced on January 4, 2019 the closing of an $85 million financing to support continued growth and innovation of its computational platform and expansion of its drug discovery pipeline.
-
You’ve Closed Your Financing Round. Congratulations. Now What?
10.27.2018In an article published by VentureBeat, Partner Gary Schall lays out the critical post-financing actions that startups should take after closing their financing rounds.
-
2018 M&A Report
6.22.2018The 2018 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2018 IPO, Venture Capital and M&A Reports
6.22.2018WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2018 IPO Report
6.22.2018The 2018 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest.
-
2018 Venture Capital Report
6.22.2018The 2018 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as provides a look at key issues to consider.
-
WilmerHale Counsels Decibel Therapeutics in $55M Series C Financing
6.20.2018Decibel Therapeutics, Inc., a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, announced on June 19, 2018, the closing of a $55 million Series C financing.
-
WilmerHale Counsels Accent Therapeutics in $40M Series A Financing
5.22.2018On May 18, 2018, Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced its $40M Series A financing.
